To determine the cost-effectiveness of standard strategy (interferon alpha) versus Cladribine (2chlorodeoxyadenosine) and Cladribine with interferon alpha treatment for patients with hairy cell leukemia. METHODS: A cost-effectiveness analysis was performed. Efficacy of standard treatment strategy, Cladribine and Cladribine with interferon treatment, was estimated from a previous clinical trial held in Moscow HRC RAMS. A total of 160 patients entered the trial. Three group patients with hairy cell leukemia were assigned to receive: 1st group-interferon alpha (3 million units thrice a week), 2nd group-Cladribine (0.1 mg/kg daily as a continuous intravenous infusion over seven days), 3rd group received Cladribine with interferon alpha. Direct medical costs (cost of drug administration, resource utilization, duration of hospitalization) were estimated. Achievement of remission was used as effectiveness. Unit costs were based on detailed data from the Moscow Medical Sechenov Academy. The rate of exchange was 24.4 rubles for USD$1. RESULTS: direct medical costs were RUR93 477 for group 1 (C1), RUR91756 for group 2 (C2) and RUR40 436 for group 3 (C3). Achievement of remission = 70.0 % (E1), 99.0% (E2), 99.0% (E3), for each group respectively. The final calculation of cost / effectiveness ratio (CER) was: CER1 = RUR131079, CER2 = RUR94421 and CER3 = RUR40845 per one patient for group 1, 2, and 3 respectively. CONCLUSION: Cladribine with interferon alpha usage versus standard therapy is more cost-effective in the treatment of patients with hairy cell leukemia. OBJECTIVE: To estimate the cost-effectiveness of pregabalin compared to gabapentin for patients with postherpetic neuralgia(PHN) in a Swedish setting. METHODS: This cost-A158 Abstracts
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COST-EFFECTIVENESS ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENTS FOR BONE MARROW TRANSPLANTATION IN PATIENTS WITH APLASTIC ANEMIA IN MEXICO
Mould-Quevedo J 1 , Contreras-Hernandez I 2 , Salinas-Escudero G 3 , Davila-Loaiza G 1 1 Pfizer Mexico, Mexico City, Mexico, 2 Social Security Mexican Institute, Mexico City, Mexico, 3 Hospital Infantil de México Federico Gomez, Mexico City, Mexico OBJECTIVE: Aplastic anemia is a rare disease but its presence could lead to patient's death and high expenses for hospitals and families. The purpose of this study was to model the economic and health consequences of cyclophosphamide + equine ATG vs. cyclophosphamide for the management of patients with aplastic anemia after bone marrow transplantation at the Social Security Mexican Institute (IMSS). METHODS: A cost-effectiveness analysis was developed based on a Bayesian decision tree model from the health care payer's perspective. Effectiveness measures were the rate of avoided acute rejected cases without complications during one-year period and total survival rate on a five-year period. Effectiveness data and transition probabilities were taken from international published literature. Comparators were cyclophosphamide (50 mg/kg) + equine-ATG (30 mg/kg) and cyclophosphamide (50 mg/kg). Resource use was obtained from a local expert panel at IMSS and direct costs were taken from official institutional databases. The model was validated and calibrated according to international pharmacoeconomics guidelines. One-way and probabilistic sensitivity analyses were performed using Monte Carlo Simulation second-order approach. RESULTS: Patients treated with cyclophosphamide + equine ATG experienced the highest clinical success rate with 17.37% while patients with monotherapy experienced 2.63% (p < 0.01). Regarding the 5-year survival rate, the combined therapy obtained 80.50% vs. cylophosphamide alone 63.40% (p < 0.01). Expected mean cost per patient with cyclophosphamide + equine ATG was US$104,773 and US$102,045 for cyclophosphamide. ICER estimated using the clinical success rate as effectiveness measure was US$185 and using 5-year survival rate was US$159. Within probabilistic sensitivity analyses, components analysis and acceptability curves showed that combined therapy was the most cost-effective therapy when WTP > US$10,000 (p < 0.05). CONCLUSION: In Mexico, the combined therapy is costeffective for the treatment of aplastic anemia. These results should be taken into account by Mexican decision makers in the management of patients with aplastic anemia after bone marrow transplantation.
PSY21 THE COST-EFFECTIVENESS OF LYRICA (PREGABALIN) IN PATIENTS WITH CENTRAL NEUROPATHIC PAIN
Ramos É, Tran T, Landry PA Pfizer Canada Inc, Kirkland, QC, Canada OBJECTIVE: Patients with chronic central neuropathic pain (CNeP) typically report considerable pain that requires frequent health care resource (HR) utilisation. The purpose of this study was to estimate the cost-effectiveness of pregabalin for the management of CNeP in a Canadian practice setting from a Ministry of Health perspective. METHODS: A stochastic simulation model was used to determine the effect of adding pregabalin to current treatment on daily pain and associated costs in a hypothetical cohort of 1000 patients with chronic CNeP. The model was based on data from a randomized, double blind, placebocontrolled, parallel-group, multicentre clinical trial of pregabalin, in which pain was evaluated using a 0-10 pain scale. Modeled Outcomes of interest included quality-adjusted lifeyears (QALYs) and mean number of days with no or mild pain (score Յ 3) over the trial duration of 12 weeks. HR utilisation (including drug costs) was assessed from a survey conducted with a group of 149 Canadian physicians and included number of physician visits, referral to specialists and waiting times, diagnostic tests and non-pharmacological treatments. Corresponding costs were obtained from Ontario Drug Benefit, London Health Sciences Centre, and the Régie de l'Assurance Maladie du Québec, and are expressed in 2007 Canadian dollars. Sensitivity analyses were conducted on model's assumptions. RESULTS: Compared with no additional treatment, treatment with pregabalin yielded a cost-utility ratio of $9648/QALY, and a costeffectiveness ratio of $10/day with no or mild pain. Sensitivity analyses suggested that resulting ratios were very robust to changes. The most prominent variation reported was for the extension of the time horizon up to 52 weeks, with a cost-utility ratio of $23,087/QALY. CONCLUSION: Model simulations demonstrate that adding pregabalin to the current pharmacotherapy received by CNeP patients, compared to no additional treatment, is a cost-effective treatment strategy.
